Interferon beta-1a in relapsing-remitting multiple sclerosis

被引：2
|
作者：
Blumhardt, L [1 ]
机构：
[1] Univ Nottingham, Div Clin Neurol, Nottingham NG7 2UH, England
来源：
HOSPITAL MEDICINE | 1999年 / 60卷 / 03期
关键词：
D O I：
10.12968/hosp.1999.60.3.1065
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The accumulated results from multiple trials have unequivocally demonstrated beneficial effects of interferon beta-1a on disease activity in relapsing-remitting multiple sclerosis, both for clinical and magnetic resonance endpoints. New data suggest that low doses administered once weekly ore relatively ineffective and that higher, more Frequent doses are required for optimal benefit.
引用
收藏
页码：192 / 195
页数：4
相关论文
共 50 条
  • [21] Impact of daclizumab versus interferon beta-1a on patient-reported outcomes in relapsing-remitting multiple sclerosis
    Liu, Ying
    Vollmer, Timothy
    Havrdova, Eva
    Riester, Katherine
    Lee, Andrew
    Phillips, Glenn
    Wang, Ping
    Sabatella, Guido
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2017, 11 : 18 - 24
  • [22] Influence of histocompatibility genes on the clinical course of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a
    Fletcher, S.
    Klein, T.
    Pollak, L.
    MULTIPLE SCLEROSIS, 2007, 13 : S200 - S201
  • [23] Health economic evaluation of interferon beta-1a versus interferon beta-1b for patients with relapsing-remitting multiple sclerosis in Switzerland
    Nuijten, M. J. C.
    Chofflon, M.
    MULTIPLE SCLEROSIS, 2007, 13 : S262 - S262
  • [24] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [25] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Sheridan M. Hoy
    CNS Drugs, 2015, 29 : 171 - 179
  • [26] Peginterferon Beta-1a: A Review of Its Use in Patients with Relapsing-Remitting Multiple Sclerosis
    Hoy, Sheridan M.
    CNS DRUGS, 2015, 29 (02) : 171 - 179
  • [27] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
    Darba, J.
    Kaskens, L.
    Sanchez-de la Rosa, R.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
  • [28] Quality of life in 1000 patients with relapsing-remitting multiple sclerosis and the impact of treatment initiation with intramuscular interferon beta-1a
    Putzki, Norman
    Hartung, Hans Peter
    MULTIPLE SCLEROSIS, 2008, 14 : S149 - S149
  • [29] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF SUBCUTANEOUS INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
    Espallardo, O.
    Crespo, C.
    Polanco, C.
    Nieves, D.
    VALUE IN HEALTH, 2009, 12 (07) : A366 - A367
  • [30] Interferon beta-1a is efficacious and well tolerated by patients with relapsing-remitting multiple sclerosis who discontinue use of interferon beta-1b
    Wabant, EL
    Beccariam, L
    Andersson, PB
    ANNALS OF NEUROLOGY, 1997, 42 (03) : T293 - T293
12345